The current therapy for resistant hypertension is often limited by hyperkalemia, renal decline, and a failure to prevent compensatory increases in circulating aldosterone. The aldosterone synthase inhibitors (ASIs) address these limitations by directly suppressing aldosterone biosynthesis sparing other steroid pathways.
